Business Context and Reporting Period
This Form 10-Q covers Gilead Sciences, Inc. for the quarterly and six-month periods ended June 30, 1997. Gilead is a biopharmaceutical company focused on research and development, with its primary commercial product being VISTIDE (cidofovir injection) for the treatment of cytomegalovirus retinitis in AIDS patients. The company achieved profitability in the second quarter of 1997, a significant shift from its historical pattern of losses, driven largely by milestone payments from collaboration agreements.
Key Financial Metrics
| Metric | Q2 1997 | Q2 1996 | 6 Months 1997 | 6 Months 1996 |
|---|---|---|---|---|
| Total Revenues | $19.7 million | $2.2 million | $25.2 million | $3.0 million |
| Net Income (Loss) | $2.7 million | ($12.2 million) | ($5.2 million) | ($23.0 million) |
| Operating Loss | ($1.4 million) | ($15.9 million) | ($13.4 million) | ($29.3 million) |
| Net Interest Income | $4.2 million | $3.7 million | $8.2 million | $6.3 million |
| Cash & Short-term Investments | $337.4 million (as of June 30, 1997) | |||
| Accumulated Deficit | $139.7 million (as of June 30, 1997) | |||
| Debt Obligations | $4.9 million total (Current: $3.1M; Noncurrent: $1.8M) |
Material Changes vs. Prior Period
- Revenue Surge: Total revenues increased 795% in Q2 1997 compared to Q2 1996. This was primarily due to approximately $13.0 million in milestone payments from collaboration agreements with Pharmacia & Upjohn (P&U) and F. Hoffmann-La Roche Ltd. (Roche).
- Profitability: The company reported a net income of $2.7 million for Q2 1997, reversing a net loss of $12.2 million in the same period in 1996. This was the first profitable quarter since the third quarter of 1996.
- R&D Expenses: Research and development expenses increased 39% to $14.7 million in Q2 1997 from $10.6 million in Q2 1996, driven by expanded clinical trials and staffing.
- SG&A Expenses: Selling, general, and administrative expenses decreased 17% to $6.1 million in Q2 1997 from $7.4 million in Q2 1996, largely due to the absence of one-time VISTIDE launch expenses incurred in 1996.
- Capital Structure: In June 1997, the company issued 1,133,786 shares of Series B Convertible Preferred Stock to P&U for approximately $40 million.
Guidance, Outlook, and Risks
Outlook: Management expects to incur losses for the next several years due to ongoing R&D programs, clinical trials, and marketing efforts for VISTIDE and other candidates. While the company achieved profitability in Q2 1997, it does not anticipate sustained profitability without significant revenue from other products in development.
Liquidity: The company believes its existing capital resources ($337.4 million in cash and short-term investments), supplemented by product and contract revenues, are adequate for the foreseeable future. However, future funding requirements may necessitate additional equity or debt financings.
Risks and Contingencies:
- R&D Uncertainty: Product candidates may fail in clinical trials, be found toxic, or fail to receive regulatory approval.
- Market Risks: Intense competition, pricing pressure from payors, and uncertainties regarding the market performance of VISTIDE.
- Forward-Looking Statements: Actual results may differ significantly from projections due to risks inherent in the pharmaceutical industry.
Investor Verification Checklist
- Verify the sustainability of revenue streams, noting that Q2 1997 profitability was heavily reliant on non-recurring milestone payments ($13.0 million) rather than product sales.
- Confirm the status and timeline of clinical trials for product candidates beyond VISTIDE, as future profitability depends on their success.
- Review the terms of the Series B Convertible Preferred Stock issued to P&U, including conversion rights and liquidation preferences.
- Monitor the trajectory of R&D expenses, which are projected to increase in the remainder of 1997.
- Assess the company's cash burn rate relative to its $337.4 million cash position to determine runway without additional financing.